CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy
With the clinical study report now complete, the final 36-month data further validate the effectiveness of VNS Therapy for severe focal seizures in both children and adults with drug-resistant epilepsy and demonstrate early and lasting outcomes.
Share
'It is critically important to conduct long-term, real-world studies like CORE-VNS, and it is pleasing to see these clinically meaningful and durable results demonstrating the effectiveness of VNS Therapy for people living with drug-resistant epilepsy,' said Arjune Sen, Professor of Global Epilepsy at The University of Oxford and Consultant Neurologist at Oxford University Hospitals NHS Foundation Trust. Prof. Sen is also coordinating investigator for the CORE-VNS study.
The CORE-VNS 36-month data analysis reaffirms the effectiveness of VNS Therapy, in pediatric and adult patients, and expands upon LivaNova's presentation of interim 24-month data evaluating the effectiveness of VNS Therapy in children ages 4 to 18 years old with focal onset seizures at the American Epilepsy Society's annual conference in December 2024. 1 Within the full 36-month analysis, the greatest proportion of patients at all ages reported focal onset seizures with impaired awareness (FIA) to be their most disabling seizure type. CORE-VNS study data demonstrate the impact of VNS Therapy, including:
In children 4 to 18 years old, FIA motor seizures, for example, reduced by a median of 87% at 36 months. Including adults, 34% of people with FIA motor seizures reported 100% seizure reduction (freedom from these seizures over the three months prior to their three-year study visit), with an overall median reduction of 80%.
In children 4 to 18 years old, focal to bilateral tonic-clonic (FBTC) seizures reduced by a median of 100% at 36 months. Including adults, 49% of people with FBTC seizures reported 100% seizure reduction at the three-year study visit, with an overall median reduction of 95%.
The effectiveness of VNS Therapy was noted as early as three months after implantation, followed by further substantial reduction noted in both FIA and FBTC seizures at the 12-, 24-, and 36-month study visits.
Unlike many long-term follow-up studies on DRE, CORE-VNS had a high patient-retention rate throughout the three years of follow-up (82%).
'LivaNova is deeply committed to advancing epilepsy research and in every study of VNS Therapy to date, we continue to see that effectiveness can be achieved early and continue to improve month by month and visit by visit. This remained true over the course of three years in CORE-VNS,' said Kathryn Nichol, Ph.D., Vice President Global Medical Affairs, LivaNova. 'Further, CORE-VNS confirms that VNS Therapy is effective for the most severe focal seizures in pediatric and adult patients. Not all seizures are created equal—this is why evaluating severe focal seizures that may have a larger impact on quality of life and outcomes in people with drug-resistant epilepsy is so important.'
CORE-VNS is the largest prospective study of VNS Therapy ever conducted worldwide. The full, 36-month CORE-VNS study results will be published later this year.
"The strong outcomes from the CORE-VNS study bolster our efforts to narrow the DRE treatment gap, increase access to care, and drive awareness of surgical therapies for this significantly under-addressed patient population,' said Stephanie Bolton, LivaNova President, Global Epilepsy.
About CORE-VNS
CORE-VNS is a real-world, long-term, open-label study focused on the outcomes of VNS Therapy™ in people diagnosed with drug-resistant epilepsy (DRE). Enrolling more than 800 people from 61 worldwide sites, the study is the most comprehensive assessment of the effectiveness of VNS Therapy to date and provides modern insights into the global use of VNS Therapy in the management and control of seizures.
Adverse events in the CORE-VNS study were typical of those reported in the product labeling and experienced following placement of a VNS Therapy device. The most commonly reported (>5%) adverse events overall included respiratory, thoracic, and mediastinal disorders (dysphonia, dyspnea, cough) and general disorders/administration site conditions. See important safety information at VNSTherapy.com/safety.
About VNS Therapy for Epilepsy
VNS Therapy™ is clinically proven safe and effective as an add-on treatment to reduce the frequency of seizures in adults and children as young as 4 years old with drug-resistant epilepsy and partial onset seizures. It is a unique treatment approach developed for people with drug-resistant epilepsy—a condition that affects approximately one in three people with epilepsy. Unlike some other surgical treatment options for people with drug-resistant epilepsy, VNS Therapy implantation involves an outpatient procedure and does not require penetration of the skull. Outside the United States, the VNS Therapy indications for use may vary. For more information, visit VNSTherapy.com.
References
About LivaNova
LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing solutions in select neurological and cardiac conditions. Headquartered in London, LivaNova employs approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals, and healthcare systems worldwide. For more information, please visit www.livanova.com.
Safe Harbor Statement
This news release contains 'forward-looking statements' concerning the Company's goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the CORE registry and VNS Therapy™ for epilepsy. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company's most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
3 hours ago
- Hamilton Spectator
VERSES® Featured in IEEE Spectrum
VANCOUVER, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSF) ('VERSES'' or the 'Company'), a cognitive computing company specializing in next-generation agentic software systems, has been featured in IEEE Spectrum, the flagship publication of the IEEE, the world's largest professional organization devoted to engineering and the applied sciences. The article, co-authored by VERSES CEO Gabriel René, addresses questions such as: Why does the Spatial Web matter? How, exactly, can it make the world better? These are answered with five example use cases for the Spatial Web: VERSES CEO Gabriel René said 'I am delighted to see our vision of the Spatial Web in IEEE Spectrum. These standards will make it easier for our product, Genius™, to interconnect a physical world-full of devices, phones, wearables, robots, drones, and even AI agents. For Genius customers, this can mean quicker development and deployment and lower integration costs.' The article can be found at: About VERSES VERSES® is a cognitive computing company building next-generation intelligent software systems modeled after the wisdom and genius of Nature. Designed around first principles found in science, physics and biology, our flagship product, Genius,™ is an agentic enterprise intelligence platform designed to generate reliable domain-specific predictions and decisions under uncertainty. Imagine a Smarter World that elevates human potential through technology inspired by Nature. Learn more at , LinkedIn and X . On behalf of the Company Gabriel René, Founder & CEO, VERSES AI Inc. Press Inquiries: press@ Investor Relations Inquiries James Christodoulou, Chief Financial Officer IR@ , +1(212)970-8889
Business Wire
3 hours ago
- Business Wire
Bradford Health Services Earns Coveted "Great Place To Work"® Certification
BIRMINGHAM, Ala.--(BUSINESS WIRE)-- Bradford Health Services, a leading provider of drug and alcohol addiction treatment across the Southeastern U.S., today announced it has been officially certified as a Great Place To Work®. This recognition, awarded by the global authority on workplace culture, underscores Bradford Health's commitment to building a supportive, inclusive, and high-trust environment for its more than 1,600 U.S.-based employees. 'This certification is a reflection of the servant-leadership philosophy that guides us at Bradford,' said Rob Marsh, Chief Executive Officer. Share Bradford Health achieved certification with 67% of employees reporting a positive experience at work, surpassing the typical U.S.-based company average of 57%. Key areas of strength highlighted by employees include: 89% agree they are entrusted with significant responsibilities. 86% say their work has special meaning beyond being 'just a job,' and that they felt welcomed upon joining. 84% affirm they feel they make a difference in the organization. 82% report they can be themselves at work. 'This certification is a reflection of the servant-leadership philosophy that guides us at Bradford,' said Rob Marsh, Chief Executive Officer. 'We've built a culture where our people come first—where leaders exist to support, uplift, and empower our teams to live out our mission with purpose and compassion.' Great Place To Work® conducts its evaluations using its proprietary Trust Index™ survey and Trust Model™, which assess culture across five pillars: credibility, respect, fairness, pride, and camaraderie. About Bradford Health Services With 40 years of experience, Bradford Health Services operates addiction treatment centers in Alabama, Florida, Mississippi, North Carolina, Tennessee, and Texas. The organization is accredited by The Joint Commission and delivers evidence-based care at every stage of the recovery journey. About Great Place To Work® Certification Great Place To Work® Certification ™ is the gold standard for workplace culture recognition. Based on anonymous employee feedback, the certification recognizes organizations that foster high levels of trust, pride, and camaraderie.
Business Wire
3 hours ago
- Business Wire
Arch Introduces New Supplemental Health Insurance Products to Help Bridge Coverage Gaps
HUNT VALLEY, Md.--(BUSINESS WIRE)--Arch Insurance's Accident & Health business unit, a leading provider of both business and consumer insurance products, is pleased to announce the launch of its new Individual Supplemental Health product suite. These products are designed to help individuals manage out-of-pocket expenses not typically covered by major medical plans, including deductibles, co-insurance and out-of-network charges through a variety of benefits including Accident Medical Expense, Hospital Indemnity, Critical Illness and Accidental Death. Arch's products provide an added layer of financial cushion when unexpected health events occur to individuals including employees, independent contractors, gig workers and association members. The products are available with no medical underwriting and are fully portable, allowing policyholders to keep their coverage through job or life changes. Arch's digital technology enables partners to generate quotes and complete enrollments in minutes. Arch's fully licensed call center provides sales and customer service support for both partners and clients. 'By offering access through our APEX™ digital platform or seamless API integration, we're making it easier than ever for our distribution partners to deliver these products efficiently and effectively to their clients,' said Jim Villa, Senior Vice President, Arch Accident & Health. For more information or to schedule a call to discuss how our individual supplemental health products can add value to your company, please visit our website or contact us at accidentandhealth@ About Arch Accident & Health Arch Accident & Health is a leading provider of innovative insurance solutions, committed to redefining industry standards through technological advancements and unparalleled client support. With a focus on excellence and a dedication to delivering value-driven products, Arch Accident & Health continues to lead the way in the insurance sector. About Arch Insurance North America Arch Insurance North America, part of Arch Capital Group Ltd., includes Arch's insurance operations in the United States and Canada. Business in the U.S. is written by Arch Insurance Company, Arch Specialty Insurance Company, Arch Property & Casualty Insurance Company and Arch Indemnity Insurance Company. Business in Canada is written by Arch Insurance Canada Ltd. About Arch Capital Group Ltd. Arch Capital Group Ltd., a publicly listed Bermuda exempted company with approximately $22.1 billion in capital at March 31, 2024, provides insurance, reinsurance and mortgage insurance on a worldwide basis through its wholly owned subsidiaries. Cautionary Note Regarding Forward-Looking Statements The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward−looking statements. This release or any other written or oral statements made by or on behalf of Arch Capital Group Ltd. and its subsidiaries may include forward−looking statements, which reflect the Company's current views with respect to future events and financial performance. All statements other than statements of historical fact included in or incorporated by reference in this release are forward−looking statements. Forward−looking statements can generally be identified by the use of forward−looking terminology such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe" or "continue" or their negative or variations or similar terminology. Forward−looking statements involve the Company's current assessment of risks and uncertainties. Actual events and results may differ materially from those expressed or implied in these statements. A non-exclusive list of the important factors that could cause actual results to differ materially from those in such forward-looking statements includes the following: adverse general economic and market conditions; increased competition; pricing and policy term trends; fluctuations in the actions of rating agencies and the Company's ability to maintain and improve its ratings; investment performance; the loss of key personnel; the adequacy of the Company's loss reserves, severity and/or frequency of losses, greater than expected loss ratios and adverse development on claim and/or claim expense liabilities; greater frequency or severity of unpredictable natural and man-made catastrophic events, including the effect of contagious diseases on our business; the impact of acts of terrorism and acts of war; changes in regulations and/or tax laws in the United States or elsewhere; ability to successfully integrate, establish and maintain operating procedures as well as integrate the businesses the Company has acquired or may acquire into the existing operations; changes in accounting principles or policies; material differences between actual and expected assessments for guaranty funds and mandatory pooling arrangements; availability and cost to the Company of reinsurance to manage our gross and net exposures; the failure of others to meet their obligations to the Company; an incident, disruption in operations or other cyber event caused by cyber attacks, the use of artificial intelligence technologies or other technology on the Company's systems or those of the Company's business partners and service providers, which could negatively impact the Company's business and/or expose the Company to litigation; and other factors identified in our filings with the U.S. Securities and Exchange Commission (SEC). The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with other cautionary statements that are included herein or elsewhere. All subsequent written and oral forward−looking statements attributable to us or persons acting on the Company's behalf are expressly qualified in their entirety by these cautionary statements. The Company's forward-looking statements speak only as of the date of this press release or as of the date they are made, and the Company undertakes no obligation to publicly update or revise any forward−looking statement, whether as a result of new information, future events or otherwise. Source — Arch Insurance North America Tag — arch-insurance
